Aeterna Zentaris Outlines Progress on Development Pipeline Programs and Provides Corporate UpdateGlobeNewsWire • 07/13/23
Aeterna Zentaris to Participate in the Virtual Investor Summer Spotlight SeriesGlobeNewsWire • 07/05/23
Aeterna Zentaris Provides Update on Macrilen® (Macimorelin), Reiterates Advancement of Pediatric DETECT TrialGlobeNewsWire • 04/05/23
Pharmanovia to Market GHRYVELIN™ (Macimorelin) in the European Economic Area (EEA) and UK as Diagnostic Test for Growth Hormone Deficiency (GHD)GlobeNewsWire • 03/16/23
Is AEterna Zentaris (AEZS) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 02/07/23
Aeterna Zentaris Provides Business Update and Outlines Key Upcoming MilestonesGlobeNewsWire • 01/17/23
Aeterna Zentaris to Present at the Virtual Investor 2023 Companies to Watch EventGlobeNewsWire • 01/10/23
Aeterna Zentaris Set to Regain Full Rights to Macrilen™ (Macimorelin) in U.S. and Canada from Novo NordiskGlobeNewsWire • 08/29/22
Aeterna Zentaris Reports Second Quarter 2022 Financial Results and Recent HighlightsGlobeNewsWire • 08/03/22
Aeterna Zentaris to Present at the H.C. Wainwright Global Investment ConferenceGlobeNewsWire • 05/18/22
Update on Positive Pre-Clinical Results from AIM Biologicals Development Program for the Potential Treatment of Parkinson's DiseaseGlobeNewsWire • 05/12/22
Aeterna Zentaris Reports First Quarter 2022 Financial Results and Provides Business OutlookGlobeNewsWire • 05/11/22